Rise and fall of 17 alfa-hydroxyprogesteronecaproate
Journal of Controversies in Obstetrics & Gynecology and Pediatrics · 2023
DOI: 10.51271/jcogp-0017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controversies in Obstetrics & Gynecology and Pediatrics, 2023. Verfasst von Nefise Nazlı Yenigül und 1 weiteren Autor:innen.
Abstract (Originalsprache)
17 alpha-hydroxyprogesteronecaproate (17-OHPC), a syntheticprogestogen, wasfirstapproved in 1956 totreat a variety of gynecological and obstetric conditions in pregnantwomen, includingthreatenedabortion and preterm birth. Itwaswidelyprescribedtopregnantwomen in the USA and Europe in the 1950s and 1960s. Studiesover time haveshownthat it is not successful in thisgroup of patients. Additionally, comparedtotheoffsprings not exposedto 17-OHPC, offspringsexposed had an increased risk of anycancer.
Zitieren
APA
Yenigül, N. N., & Dilbaz, B. (2023). Rise and fall of 17 alfa-hydroxyprogesteronecaproate. Journal of Controversies in Obstetrics & Gynecology and Pediatrics. https://doi.org/10.51271/jcogp-0017
Vancouver
Yenigül NN, Dilbaz B. Rise and fall of 17 alfa-hydroxyprogesteronecaproate. Journal of Controversies in Obstetrics & Gynecology and Pediatrics. 2023. doi:10.51271/jcogp-0017
BibTeX
@article{Yenigl2023,
author = {Yenigül, Nefise Nazlı and Dilbaz, Berna},
title = {Rise and fall of 17 alfa-hydroxyprogesteronecaproate},
journal = {Journal of Controversies in Obstetrics & Gynecology and Pediatrics},
year = {2023},
doi = {10.51271/jcogp-0017}
}
EUVIMED